as 06-28-2024 4:00pm EST
Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. The consumer group is being divested in 2023 under the new name Kenvue. Geographically, just over half of total revenue is generated in the United States.
Founded: | 1886 | Country: | United States |
Employees: | N/A | City: | NEW BRUNSWICK |
Market Cap: | 354.2B | IPO Year: | 1944 |
Target Price: | $175.17 | AVG Volume (30 days): | 7.4M |
Analyst Decision: | Buy | Number of Analysts: | 12 |
Dividend Yield: | 3.39% | Dividend Payout Frequency: | Quarterly |
EPS: | 15.09 | EPS Growth: | 216.35 |
52 Week Low/High: | $143.13 - $175.97 | Next Earning Date: | 07-17-2024 |
Revenue: | $81,796,000,000 | Revenue Growth: | 5.60% |
Revenue Growth (this year): | 4.88% | Revenue Growth (next year): | 2.86% |
Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
Broadhurst Vanessa | JNJ | EVP, Global Corp Affairs | Mar 13 '24 | Sell | $162.16 | 8,891 | $1,441,764.56 | 15,043 | SEC Form 4 |
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
Yahoo Finance Video
2 days ago
MT Newswires
2 days ago
PR Newswire
2 days ago
Simply Wall St.
2 days ago
Zacks
3 days ago
Motley Fool
3 days ago
Motley Fool
3 days ago
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.